AKT1 and familial pancreatic carcinoma: Finally, PI3K/AKT has been shown to be also one of the mediators of chemo-resistance to gemcitabine in pancreatic cancer, and the use of PI3K inhibitors like wortmannin and LY294002 increased the sensitivity of PDAC cells to gemcitabine [54].